Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1
Clinical Pharmacology & TherapeuticsPublished 1 July 2004
Alex Sparreboom
Citations239
SJR quartileQ1
SJR score2.13
SNIP1.86
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
An exploratory analysis was performed to evaluate the effects of the natural allelic variant ABCG2 421C>A on the pharmacokinetics of diflomotecan.
Abstract
These findings provide the first evidence linking variant ABCG2 alleles to altered drug exposure and suggest that interindividual variability in substrate drug effects might be influenced, in part, by ABCG2 genotype.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
Proceedings of the National Academy of SciencesFunctional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity <i>in</i> <i>vivo</i>
2,363 Citations2000Sven Hoffmeyer, Oliver Burk +9 more
A significant correlation of a polymorphism in exon 26 (C3435T) of MDR-1 with expression levels and function is observed and this polymorphism is expected to affect the absorption and tissue concentrations of numerous other substrates of M DR-1.
Proceedings of the National Academy of SciencesA multidrug resistance transporter from human MCF-7 breast cancer cells
2,311 Citations1998L. Austin Doyle, Weidong Yang +5 more
Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicsin, which causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells.
Nature GeneticsSequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
2,161 Citations2001Peter Kuehl, Jiong Zhang +17 more
CYP3A5 was more frequently expressed in livers of African Americans than in those of Caucasians, and may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.
PubMedSubcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
1,128 Citations2001Marc Maliepaard, George L. Scheffer +7 more
The apical localization in the epithelium of the small intestine and colon indicates a possible role of BCRP in the regulation of the uptake of p.o. delivered B CRP substrates by back-transport of substrate drugs entering from the gut lumen and is consistent with the hypothesis of a protective role ofBCRP for the fetus.
Clinical Pharmacology & TherapeuticsIdentification of functionally variant MDR1 alleles among European Americans and African Americans
1,008 Citations2001Ryeo Won Kim
Allelic variation in MDR1 is more common than previously recognized and involves multiple SNPs whose allelic frequencies vary between populations, and some of these SNPs are associated with altered P‐glycoprotein function.
Advanced Drug Delivery ReviewsGenetic contribution to variable human CYP3A-mediated metabolism
984 Citations2002Jatinder K. Lamba, Yvonne S. Lin +2 more
The human CYP3A subfamily plays a dominant role in the metabolic elimination of more drugs than any other biotransformation enzyme and may be implicated in disease risk and the metabolism of endogenous steroids or xenobiotics in these tissues.
Proceedings of the National Academy of SciencesThe breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria
821 Citations2002Johan W. Jonker, Marije Buitelaar +10 more
The results indicate that humans or animals with low or absent BCRP activity may be at increased risk for developing protoporphyria and diet-dependent phototoxicity and provide a striking illustration of the importance of drug transporters in protection from toxicity of normal food constituents.
PubMedMolecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
820 Citations1999Keisuke Miyake, Lyn A. Mickley +9 more
High levels of expression in the S1-M1-80 cells and in the human breast cancer subline, MCF-7 AdVp3000, are consistent with the identification of a new ATP binding cassette transporter, which is overexpressed in mitoxantrone-resistant cells.
PubMedA human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.
800 Citations1998R Allikmets, Lynn M. Schriml +3 more
The abundant expression of this gene in the placenta suggests that the protein product has an important role in transport of specific molecule(s) into or out of this tissue.
PharmacogeneticsThe genetic determinants of the CYP3A5 polymorphism
669 Citations2001Elisabeth Hustert, Michael Haberl +14 more
Investigation of the expression of CYP3A5 and its genetic determinants in a panel of 183 Caucasian liver samples reports that a SNP within intron 3 (g.6986G>A) is the primary cause of the CYP4A5 protein polymorphism, and should add to efforts to identify clinically relevant, CYP2A5-specific reactions and to further elucidate traits responsible for variable expression of the entire CYP 3A family.
Clinical Pharmacology & TherapeuticsGenetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
654 Citations2003Dennis A. Hesselink
The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus have a narrow therapeutic index and show considerable interindividual variability in their pharmacokinetics.
JNCI Journal of the National Cancer InstituteRole of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
639 Citations2000Johan W. Jonker
Bcrp1 mediates apically directed drug transport, appears to reduce drug bioavailability, and protects fetuses against drugs, and it is proposed that strategic application of BCRP inhibitors may lead to more effective oral chemotherapy with topotecan or other B CRP substrate drugs.
PubMedOverexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
487 Citations1999Marc Maliepaard, M A van Gastelen +6 more
It is reported for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that B CRP-mediated efflux of topOTecan is very efficient.
PubMedC421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
441 Citations2002Yasuo Imai, Minoru Nakane +6 more
People with C376T and/or C421A polymorphisms may express low amounts of BCRP, and this low BCRp expression might result in hypersensitivity of normal cells to such anticancer drugs as irinotecan and mitoxantrone.
PubMedAcquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
429 Citations2001Yasuyuki Honjo, Christine A. Hrycyna +7 more
It is suggested that amino acid 482 has a crucial role in MXR/BCRP/ABCP function and that mutation of a single amino acid residue significantly changes substrate specificity, thus altering the drug resistance phenotype.
JNCI Journal of the National Cancer InstituteAtypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines
348 Citations1999D D Ross, Weidong Yang +8 more
Overexpression of BCRP mRNA is frequently observed in multidrug-resistant cell lines selected with mitoxantrone, suggesting that B CRP is likely to be a major cellular defense mechanism elicited in response to exposure to this drug.
PubMedTransport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
306 Citations2003Zhe‐Sheng Chen, Robert W. Robey +7 more
It is demonstrated that R482 mutations observed in drug-resistant cell lines have profound effects on the in vitro transport properties of the pump, indicating that ABCG2 is a component of the energy-dependent efflux system for certain folates and antifolates, but that its transport characteristics with respect to polyglutamates and reduced folates are not identical to those of multidrug resistance protein family members.
Journal of Clinical OncologyOral chemotherapy: rationale and future directions.
294 Citations1998Mark DeMario, Mark J. Ratain
Oral chemotherapy represents a fundamental change in contemporary oncology practice, driven by pharmacoeconomic issues, patient convenience, and the potential for improved patient quality of life.
PharmacogeneticsNatural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine
271 Citations2003Charis P Zamber, Jatinder K. Lamba +5 more
Common natural allelic variants of BCRP have been identified, and did not influence interindividual variation in expression of B CRP mRNA in human intestine, but remain to be tested for their effect on BCRp function.
PubMedCamptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
261 Citations1999Mariafiorella Brangi, Thomas Litman +8 more
It is concluded that colon and breast cancer cells have a capacity for glucuronidation that could contribute to intrinsic drug resistance in colon cancer cells and may be acquired in breast cancers cells.
PubMedIrinotecan pathway genotype analysis to predict pharmacokinetics.
258 Citations2003Ron H.J. Mathijssen, Sharon Marsh +6 more
It is concluded that genotyping for ABCB1 1236C>T may be one of the factors assisting with dose optimization of irinotecan chemotherapy in cancer patients and additional investigation is required to confirm these findings in a larger population.
PharmacogeneticsIdentification and functional characterization of eight CYP3A4 protein variants.
231 Citations2001Regina Eiselt, Tammy L. Domanski +12 more
A study of 213 Middle and Western European DNA samples resulted in the identification of 18 new CYP3A4 variants, including eight protein variants that may play a role in the atypical response to drugs or altered sensitivity to carcinogens.
Drug Resistance UpdatesPharmacogenomics of ABC transporters and its role in cancer chemotherapy
223 Citations2003Alex Sparreboom, Romano Danesi +3 more
This review focuses on recent advances in the pharmacogenomics of ABC transporters, and discusses potential implications of genetic variants for the chemotherapeutic treatment of cancer.
PubMedWild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
216 Citations2003Erin L. Volk, Erasmus Schneider
Evidence is provided for BCRP as a MTX-transporter using an in vitro membrane vesicle system and a possible mechanism by which it confers resistance is revealed.
PubMedMultidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2).
193 Citations2002John Allen, Alfred H. Schinkel
The P-gp, MRP1, and MRP2 transporters have all been found to confer MDR to cancer cells and mediate extensive protection of intact organisms against the toxic action of (anticancer) drugs and toxins.
Biochemical and Biophysical Research CommunicationsTransport of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Breast Cancer Resistance Protein ABCG2 in Human Lung Cancer Cells
187 Citations2001Katsumi Nakatomi, Megumi Yoshikawa +10 more
Findings suggest that BCRP expressed in PC-6/SN2-5H cells transports bothSN-38 and SN-38-glucuronide with a higher affinity toward SN- 38.
Biochemical and Biophysical Research CommunicationsThe Product of the ABC Half-Transporter Gene ABCG2 (BCRP/MXR/ABCP) Is Expressed in the Plasma Membrane
184 Citations2000Emmanuelle Rocchi, Alexey Khodjakov +5 more
This protein is highly overexpressed in several drug-resistant cell lines and localizes predominantly to the plasma membrane, instead of to intracellular membranes as seen with all other known half-transporters.
PubMedA mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.
140 Citations2002John Allen, Sonja C Jackson +1 more
It is found that the Bcrp1 mutations all occurred after previous amplification and overexpression of the wild- type gene under doxorubicin selection; wild-type BCRP1 is evidently able to mediate substantial resistance to anthracyclines, and this was confirmed in BCrp1-transduced cell lines.
Journal of Bioenergetics and BiomembranesThe Role of Half-Transporters in Multidrug Resistance
128 Citations2001Susan E. Bates, Robert W. Robey +4 more
These newly identified transporters include additional members of the MRP family, ABC2, and a new half-transporter, MXR/BCRP/ABCP1, which confers high levels of resistance to mitoxantrone, anthracyclines, and the camptothecins SN-38 and topotecan.
PubMedPharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy.
123 Citations2003A. Craig Lockhart, Rommel G. Tirona +1 more
The ATP-binding cassette (ABC) transporters belong to the largest known transporter gene family and translocate a variety of substrates including chemotherapy agents and their naturally occurring genetic polymorphisms in cancer and chemotherapy is reviewed.
Journal of Human GeneticsCatalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8
120 Citations2002Aritoshi Iida, Shigeru Saito +7 more
It is determined that 491 (81%) of the SNPs reported here were novel, and the high-density SNP maps constructed on the basis of these data should provide useful information for investigating associations between genetic variations and common diseases or responsiveness to drug therapy.
PubMedABC transporters and inhibitors: new targets, new agents.
113 Citations2002Gregory D. Leonard, Orsolya Polgár +1 more
PubMedDifferential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
74 Citations2003Rajeev Rajendra, Murugesan Gounder +6 more
It is suggested that wild-type as well as R482T BCRP mediates cellular efflux of 9-AC but not 9-NC, and polar groups at the 9 or 10 position of the CPT A ring facilitate interaction with B CRP and have implications for the clinical development of new CPT analogues.
PubMedPhase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
39 Citations2003Hans Gelderblom, Ramón Salazar +10 more
The recommended oral diflomotecan dose for Phase II studies is 0.27 mg/day x 5 every 3 weeks, which is convenient and generally well tolerated with a favorable pharmacokinetic profile and high but variable bioavailability.
Humana Press eBooksPharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms
24 Citations2003Christine M. Rose, Sharon Marsh +2 more